Osteoporosis Drug May Reduce Alzheimer’s Risk, Study Finds | HKUMed Research

A common osteoporosis medication, nitrogen-containing bisphosphonates (NBPs), may significantly lower the risk of Alzheimer’s disease and related dementias (ADRD) in older adults, according to a new study from the University of Hong Kong (HKUMed). The research, published in Alzheimer’s & Dementia, suggests a potential link between bone health treatment and cognitive protection, offering a promising avenue for preventing these debilitating conditions.

Study Details and Population

The HKUMed research team analyzed data from a healthcare database in Hong Kong, focusing on individuals aged 60 and over diagnosed with osteoporosis or fragility fractures between 2005 and 2020. The study involved a large cohort – over 120,000 patients – and employed a sophisticated matching technique. Researchers compared patients receiving NBPs to those receiving other anti-osteoporosis medications (“non-NBPs”) and an untreated control group, using a time-dependent propensity score to account for differences in patient characteristics and treatment patterns. Follow-up continued until December 31, 2021. The full study methodology is available in Alzheimer’s & Dementia.

Fragility fractures, such as hip or vertebral fractures resulting from minor trauma, are a key indicator of osteoporosis – a condition characterized by weakened bones. Osteoporosis itself doesn’t directly cause dementia, but the study suggests that treating the underlying bone loss with NBPs may have a protective effect on cognitive function.

What are Nitrogen-Containing Bisphosphonates?

Bisphosphonates are a class of drugs primarily used to increase bone density and reduce the risk of fractures in people with osteoporosis. Nitrogen-containing bisphosphonates (NBPs) are a more potent subclass of these medications. They perform by slowing down bone breakdown, allowing bones to develop into stronger and less prone to fractures. Common NBPs include alendronate, risedronate, ibandronate, and zoledronic acid. They are typically prescribed for individuals with a history of osteoporosis or fragility fractures, or those at high risk of developing these conditions.

The Link to Dementia: What the Research Shows

The study found that patients receiving NBPs experienced a reduced risk of Alzheimer’s disease and related dementias compared to the other groups. While the exact magnitude of the risk reduction requires further investigation, initial findings are encouraging. HKUMed reports that the medication may significantly reduce the risk of ADRD. It’s important to note that this research doesn’t prove a direct causal relationship; it identifies an association that warrants further exploration.

Alzheimer’s disease and related dementias are progressive neurodegenerative conditions that affect memory, thinking, and behavior. They represent a significant public health challenge, with an increasing global prevalence as populations age. Finding potential preventative strategies, like the one suggested by this study, is therefore a high priority.

Understanding Risk and Limitations

It’s crucial to understand that the study demonstrates an association, not causation. While the researchers controlled for numerous factors, it’s possible that other unmeasured variables could contribute to the observed relationship. For example, individuals prescribed NBPs may be more likely to engage in other health-promoting behaviors, such as regular exercise and a healthy diet, which could independently reduce their risk of dementia.

The study population was limited to residents of Hong Kong, which may limit the generalizability of the findings to other populations with different genetic backgrounds, lifestyles, and healthcare systems. Further research is needed to confirm these results in diverse populations and to determine the optimal dosage and duration of NBP treatment for potential cognitive benefits. The researchers also acknowledge that the study relied on observational data, which is inherently susceptible to biases. More information about the study’s scope and limitations can be found on the HKU website.

What Does This Mean for Patients?

This research does *not* mean that people should start taking osteoporosis medication solely to prevent dementia. NBPs are prescribed for the treatment of osteoporosis and fragility fractures, and their employ should be guided by a qualified clinician based on individual risk factors and medical history.

If you are already taking an NBP for osteoporosis, there is no need to make any changes to your treatment plan. However, you should discuss any concerns you have with your doctor. If you are concerned about your risk of dementia, the best course of action is to focus on modifiable risk factors, such as maintaining a healthy lifestyle, controlling blood pressure and cholesterol, and engaging in regular physical and mental activity.

The Next Steps in Research

The findings from this study are likely to stimulate further research into the potential neuroprotective effects of NBPs. Future studies could include randomized controlled trials, which are considered the gold standard for establishing causality. These trials would involve randomly assigning participants to receive either NBPs or a placebo, and then comparing the incidence of dementia between the two groups.

Researchers are also investigating the underlying mechanisms by which NBPs might protect against dementia. One hypothesis is that NBPs may reduce neuroinflammation, a process that contributes to the development of Alzheimer’s disease. Another possibility is that NBPs may improve cerebral blood flow, which is essential for brain health. Understanding these mechanisms could lead to the development of new therapies for preventing and treating dementia.

Ongoing surveillance of large healthcare databases, like the one used in this study, will also be crucial for monitoring the long-term effects of NBP treatment on cognitive function. This type of research can help to identify potential benefits and risks, and to refine treatment guidelines.